biostudies-literatureUnknown15Gribben JG<h4>Introduction</h4>The objectives of this study were to identify key treatment attributes that drive physician and patient preferences for second line (2L) and third line (3L) treatments in relapsed/refractory (R/R) follicular lymphoma (FL).<h4>Methods</h4>A multi- country, internet-based survey was administered to patients(N=195) with R/R FL and treating physicians (N=300) from the United States, United Kingdom, France, Germany, Brazil, and Japan. The survey included two discrete choice experiments - one for 2L and one for 3L treatment options - that prompted respondents to select their preferred option between two hypothetical treatment profiles varying on seven attributes associated with treatment for R/RFL: progression-free survival (PFS), overall survival (OS), serious adverse eventFrontiers in oncology1589722https://www.ebi.ac.uk/biostudies/studies/S-EPMC12287033biostudies-literaturePatient and physician treatment preferences in relapsed/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and Japan.PMC12287033Patel AKopenhafer LGribben JGBeygi SRay MBeusterien KWill OBall GPalivela MGhione PKrupsky KBest TBachy EfalsePatient and physician treatment preferences in relapsed/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and Japan.<h4>Introduction</h4>The objectives of this study were to identify key treatment attributes that drive physician and patient preferences for second line (2L) and third line (3L) treatments in relapsed/refractory (R/R) follicular lymphoma (FL).<h4>Methods</h4>A multi- country, internet-based survey was administered to patients(N=195) with R/R FL and treating physicians (N=300) from the United States, United Kingdom, France, Germany, Brazil, and Japan. The survey included two discrete choice experiments - one for 2L and one for 3L treatment options - that prompted respondents to select their preferred option between two hypothetical treatment profiles varying on seven attributes associated with treatment for R/RFL: progression-free survival (PFS), overall survival (OS), serious adverse event2025-01-01T00:00:00Z20252026-03-27T16:09:25.074Z2025-08-30T03:05:44.898ZS-EPMC122870334070893510.3389/fonc.2025.1589722